Amid outrage about sudden price hikes of specialty drugs, a company has reneged on its recent acquisition of a tuberculosis medication, a deal that would have increased the cost of the treatment more than 20-fold. Just three weeks after purchasing the rights to the drug, Rodelis Therapeutics has agreed to return the medication to the nonprofit that previously owned it.
... Read more
No comments:
Post a Comment